EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Model‐Informed Precision Dosing of Busulfan for Children and Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Critical Evaluation of Current PK Models and Dose Recommendations

Rashudy F Mahomedradja iD, Tim Bognàr iD, Kaj E van Schie, Ilse T Kuipers, Moniek A de Witte iD, Jurgen H E Kuball iD, Erfan Nur iD, Bram J Wilhelm iD, Marise R Heerma van Voss iD, Linda Franken iD, Arief Lalmohamed iD, Eleonora Noortje L Swart iD und 2 weitere

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3748 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Rashudy F Mahomedradja und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy, Division of Clinical Pharmacology, Department of Hospital Pharmacy, Noordwest Ziekenhuisgroep, Alkmaar, The Netherla…. Hauptthemen laut MEDLINE: Busulfan, Hematopoietic Stem Cell Transplantation, Models, Biological. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Busulfan is administered intravenously in conditioning regimens prior to allogeneic hematopoietic stem cell transplantation (HSCT), with model‐informed precision dosing (MIPD) targeting a 4‐day cumulative AUC of 80–100 mg*hour/L. Three pharmacokinetic (PK) models—Bognar, Langenhorst, and McCune—were evaluated using data with a minimum of 1 and a median of 2 PK sampling days from pediatric and adult patients at two tertiary hospitals in the Netherlands. Simulations with the best‐performing model evaluated dose optimization and the role of therapeutic drug monitoring (TDM). The Bognar and Langenhorst models, with overlapping datasets (25% between models, 21% with the current), accurately described busulfan concentration‐time curves in all 535 patients (0.18–72 years), especially in those > 60 years (bias and precision in clearance; −5.6%, 6.48% and 16.55%, 16.95%; in observed concentrations −1.86%, −6.52% and 9.12%, 3.58% for both models > 60 years). The McCune model underestimated clearance by 36% in children < 2 years of age. Despite accounting for age‐dependent glutathione depletion, the Langenhorst model did not outperform the simpler Bognar model. Model‐based initial dosing did not improve target attainment over SmPC‐based dosing. However, TDM‐based MIPD with a single TDM on days 2–4 significantly improved target attainment (49% vs. 87%), with a number needed to treat for TDM of 2.5. This study demonstrates the clinical efficacy of simple PK models such as the Bognar model, providing that simplicity does not compromise performance. It highlights the inadequacy of nomogram‐based dosing alone and reinforces the critical role of TDM in optimizing busulfan exposure for pediatric and adult myeloablative HSCT patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BusulfanHematopoietic Stem Cell TransplantationModels, BiologicalHumansChildAdultAdolescentChild, PreschoolDrug MonitoringMiddle AgedYoung AdultInfantMaleFemaleAgedTransplantation ConditioningTransplantation, HomologousArea Under CurvePrecision MedicineDose-Response Relationship, DrugAge FactorsNetherlandsComputer Simulation

Substanzen

Busulfan

Autor:innen und Institutionen

  • Department of Hospital Pharmacy, Division of Clinical Pharmacology, Department of Hospital Pharmacy, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands.
  • Department of Internal Medicine, Unit Pharmacotherapy, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Department of Clinical Pharmacy, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, The Netherlands.
  • Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Department of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

ORCID-Profile: Rashudy F Mahomedradja, Tim Bognàr, Moniek A de Witte, Jurgen H E Kuball, Erfan Nur, Bram J Wilhelm, Marise R Heerma van Voss, Linda Franken, Arief Lalmohamed, Eleonora Noortje L Swart, Imke H Bartelink

Zitieren

APA

Mahomedradja, R. F., Bognàr, T., van Schie, K. E., Kuipers, I. T., de Witte, M. A., Kuball, J. H. E., Nur, E., Wilhelm, B. J., Heerma van Voss, M. R., Franken, L., Lalmohamed, A., Swart, E. N. L., de Leeuw, D. C., & Bartelink, I. H. (2025). Model‐Informed Precision Dosing of Busulfan for Children and Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Critical Evaluation of Current PK Models and Dose Recommendations. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3748

Vancouver

Mahomedradja RF, Bognàr T, van Schie KE, Kuipers IT, de Witte MA, Kuball JHE, et al. Model‐Informed Precision Dosing of Busulfan for Children and Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Critical Evaluation of Current PK Models and Dose Recommendations. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3748

BibTeX
@article{Mahomedradja2025,
  author = {Mahomedradja, Rashudy F and Bognàr, Tim and van Schie, Kaj E and Kuipers, Ilse T and de Witte, Moniek A and Kuball, Jurgen H E and Nur, Erfan and Wilhelm, Bram J and Heerma van Voss, Marise R and Franken, Linda and Lalmohamed, Arief and Swart, Eleonora Noortje L and de Leeuw, Dave C and Bartelink, Imke H},
  title = {Model‐Informed Precision Dosing of Busulfan for Children and Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Critical Evaluation of Current PK Models and Dose Recommendations},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3748}
}
Kostenlos starten →